Alopecia Areata: Good Response to Treatment with Fractional Laser in 5 Cases

Nerea Landa Gundin, Marta Mendieta Eckert and Raquel Lambea Crespo

Dermitek Clinic, Paseo Uribitarte 11-12 Bajo, 48001 Bilbao, Spain

Corresponding author: Marta Mendieta Eckert, Dermitek Clinic, Paseo Uribitarte 11-12 Bajo, 48001 Bilbao, Spain, Tel: +34 652749980; Fax: +34 944010111; E-mail: mmendieta@dermitek.com

Received date: March 20, 2016; Accepted date: April 05, 2016; Published date: April 09, 2016

Introduction

Alopecia areata is a chronic inflammatory disease that results in a non-scarring hair loss. It occurs as an acute and complete loss of hair in a single or several areas, classically with morphology of circles and in the course of a few weeks. It can affect areas of the scalp, beard, eyebrows, eyelashes or be generalized being called alopecia universalis. The incidence appears to be similar in different countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2]. Its cause is unknown and nowadays is classified as an autoimmune disease with genetic predisposition, as there is some family tendency [1]. A known trigger is the sustained stress, in which case appears to be different in countries. It affects both sexes equally and all ages [1,2].

Case Reports

We present five patients with diagnosis of patchy alopecia areata localized in the scalp, one with a plaque in the eyebrow and other in the beard. The diagnosis of alopecia areata was performed clinically. Three were women and two men with ages 44 to 59 years (mean age 48.8 years). The time of diagnosis of alopecia areata ranged from 1 month to 19 years (median 2 years). Three patients had received treatment with intralesional corticosteroids or topical minoxidil before. One had never had any episode of alopecia areata before and had not received any treatment. The time of progression of the new episode ranged from 1 to 9 months. In three cases the emotional stress was identified as a trigger, while in the rest there was no apparent trigger. Patients have no known endocrine disorder.

All of them were treated with non-ablative 1550 nm erbium glass fractional laser (Fraxel®, Solta Medical). 2 to 3 sessions were performed, with an interval of 3-6 weeks and the following parameters: fluences ranging from 30-45 mJ/cm², 6-8 density and 8-10 passes. The treatment was performed without local anesthesia with an air cooling system. The results were evaluated by a dermatologist on a visual global improvement score scale: 0-25% improvement, 26-50%, 51-75% and greater than 75%. The onset of response was seen early at 2 weeks (Figures 1 and 2). All patients obtained a fully or almost fully regrowth at 3 months (Figures 3 and 4). No recurrence of the same plaques was observed in a follow up of 2 to 4 years but new plaques were developed in the patient with alopecia areata of 19 years of evolution. In all cases the regrowth of hair appeared with terminal hair and in its original color.

No side effects were reported except pain during treatment that was well tolerated.

Discussion

Treatment of alopecia areata is based in that hair follicles are preserved so the potential for recovery of hair growth is maintained. The use of light systems to stimulate hair growth is known for years. Several types of wavelength of the electromagnetic spectrum (like UVA, UVB and infrared radiation) have been used with varying results and proposed with an evidence level of 3 [1,6-10]. Infrared radiation can be emitted in the form of simple light multidirectional not coherent type diodes, as laser rays unidirectional and coherent or even mixed forms on devices that include both types of light. These new sources of light called low level laser therapy (LLLT) are spreading to androgenetic alopecia as hats or helmets for home use [11]. A study with 34 resistant patches treated with a low-level invisible pulsed infrared diode laser (904 nm) showed regrowth of hair in 94% patches. Besides, in 75% of them the regrowth was as early as 1 week after the first session [10]. However, our experience with LLLT in alopecia areata is restricted to a case of eyebrow alopecia where we had no results after 12 sessions of red light 630 nm, 20-30 mJ, 23 min/session.

A Korean group of has published a case of alopecia areata that regrew after 1 session of fractional laser [12]. Afterwards other cases have been published and it has been proposed too as a treatment for female pattern hair loss [13]. Fractional light sources are lasers that emit radiation in micro fractional columns of light that penetrate the dermis and produce heat [13-15]. The epidermis receives minimal damage that is recovered in days, which is one of its greatest advantages. Besides, it cannot produce hair removal because it has no affinity for melanin. A fractional laser can penetrate 3-4 mm into the dermis, depositing thermal energy where the dermal papilla is, which is where the capillaries are surrounding the hair germ cells [16]. It has been suggested that fractional laser could act by inducing T-cell apoptosis, wounding increased blood flow and promoting telogen to anagen transitions [12,13,15]. Recently, a murine model study showed anagen induction related to Wnt/β-catenin pathway after fractional
laser treatment, resulting in hair regrowth and proportion of anagen increased in histological examination [17].

<table>
<thead>
<tr>
<th>S.N</th>
<th>Age</th>
<th>Trigger</th>
<th>Previous treatment</th>
<th>Location</th>
<th>Size</th>
<th>Time to progression</th>
<th>Fraxel parameters</th>
<th>Number of sessions</th>
<th>Response</th>
<th>Follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>44 M</td>
<td>Stress</td>
<td>Il corticosteroids</td>
<td>Eyebrow</td>
<td>Unknown</td>
<td>1 m</td>
<td>40-45 mJ/8, 8-10 passes</td>
<td>3</td>
<td>51-75% at 1 m</td>
<td>4 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Temporal</td>
<td>40 × 30 mm</td>
<td>2 m</td>
<td>30-40 mJ/ 6-8, 8 passes</td>
<td></td>
<td></td>
<td>51-75% at 1 m; &gt;75% at 3 m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occipital</td>
<td>20 × 20 mm</td>
<td>2 m</td>
<td>30-40 mJ/ 6-8, 8 passes</td>
<td></td>
<td></td>
<td>25-50% at 1 m; &gt;75% at 3 months</td>
</tr>
<tr>
<td>2</td>
<td>59 F</td>
<td>Unknown</td>
<td>Il corticosteroids</td>
<td>Frontal</td>
<td>50 × 40 mm</td>
<td>1 m</td>
<td>35 mJ/8, 8 passes</td>
<td>2</td>
<td>&gt;75% at 3 m</td>
<td>2 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>topical minoxidil</td>
<td>Fronto- temporal</td>
<td>70 × 50 mm</td>
<td>9 m</td>
<td>35-40 mJ/8, 8-10 passes</td>
<td>3</td>
<td>&gt;75% at 2 m</td>
<td>2 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occipital</td>
<td>20 × 20 mm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>45 F</td>
<td>Unknown</td>
<td>Il corticosteroids</td>
<td>Frontal</td>
<td>50 × 40 mm</td>
<td>1 m</td>
<td>35 mJ/8, 8 passes</td>
<td>2</td>
<td>&gt;75% at 3 m</td>
<td>2 years</td>
</tr>
<tr>
<td>4</td>
<td>None</td>
<td>Beard</td>
<td></td>
<td>Frontal</td>
<td>20 × 20 mm</td>
<td>1 m</td>
<td>40 mJ/8, 8 passes</td>
<td>3</td>
<td>51-75% at 1 m</td>
<td>3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70 × 50 mm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>None</td>
<td>Occipital</td>
<td></td>
<td>Frontal</td>
<td>30 × 30 mm</td>
<td>1 m</td>
<td>40 mJ / 8, 8 passes</td>
<td>2</td>
<td>&gt;75% at 2 m</td>
<td>2 years</td>
</tr>
</tbody>
</table>

M: male; F: female; y: years; il: intralesional; m: months

Table 1: Description of the 5 cases, parameters and responses.

Our group has extensive experience in laser hair removal since 1998. We were among the first groups to describe the stimulation of hair removal laser, one of the most unknown and interesting side effects of this treatment [18]. We also make our own hypothesis that stimulation of hair happens by such energies, which are not high enough to destroy the germ cells but are sufficient to stimulate the growth of short fine clear hair to thicker, long and dark. We believe it could be by increasing blood flow in the dermal papilla, secondary to thermal stimulus.

Bolstered by this hypothesis we encourage treating these patients with alopecia areata with a heating system capable of penetrating up to dermal papilla and stimulate blood flow. A laser capable of penetrating with sufficient energy to the papillae, without destroying output, can accelerate hair in alopecia areata. All of our five patients treated had
good results that suggest that the dermal heat introduced acts as hair growth stimulant in general and in alopecia areata in particular.

The high rate of spontaneous remission makes difficult to assess the efficacy, however, regrowth cannot be expected before 3 months [1]. In patient 1, the output of hair with laser was faster than with intralesional corticosteroids. Compared with the treatments of choice, conventional and laser therapy, due to what it is important that the corticosteroids. It could be due to the thermal energy being distributed more homogeneously than the drug. Another advantage is that the laser can avoid skin atrophy of steroids, diphencyprone or minoxidil and at 4-6 weeks with intralesional or systemic corticosteroids [5,19].

It could be interesting in monotherapy as in our cases or even in a combined therapy with conventional treatments that could have synergistic effect [20].

**Conclusion**

In conclusion, we propose that a fractional laser capable of producing heat in papillary dermis can stimulate hair output in alopecia areata, being quickly, evenly and safe. More studies are needed to confirm these results and determine optimal therapeutic parameters.

**References**

19. Tosti A, Jorizzo M, Botta GL, Milani M (2006) Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized,